🟢 Telix Pharmaceuticals is trading 5% up in pre-market after completing Phase 3 BiPASS enrollment

Telix Pharmaceuticals is trading 5.25% up at $11.42 after announcing completion of patient enrollment in the Phase 3 BiPASS study and alignment with the FDA on a potential NDA pathway.

• If approved, BiPASS could support new-product reimbursement and broaden access to Illuccix and Gozellix for pre-biopsy prostate-cancer imaging.
• Telix Pharmaceuticals appointed David Gill as Chair.
• The market backdrop remains risk-off, making the company-specific clinical update the likeliest catalyst.